Overcoming methotrexate intolerance in a paediatric cohort of patients with rheumatic diseases: successful application of a large interval oral split-dose regimen
Authors' conclusion
Switching patients with MTX intolerance to the LIOS MTX regimen allows for long-term continuation of treatment and maintaining disease remission while significantly reducing side effects.
Study context
- Population
- Paediatric patients with rheumatic diseases and methotrexate (MTX) intolerance wanting to discontinue once-weekly MTX
- Participants
- 26 patients
- Exposure
- LIOS MTX regimen vs prior once-weekly MTX
- Outcome
- MTX intolerance (MISS) before vs after switching
- Follow-up
- Six months
Methodological detailsbefore-and-after comparison
- Before-and-after comparison
Main finding
As reported in the abstract
MISS, average · 6 months
Average Methotrexate Intolerance Severity Score (MISS) before switching to LIOS MTX regimen
12.3
Average MISS after six months on LIOS MTX regimen
2.8
Observational data: associations, not effects.
Further findings
Compliance with MTX treatment after switching to LIOS MTX regimen
- All patients compliant for at least 8 months; median 22 months
Parental psychological distress during drug administration improved
- Cases with improvement
- 24 out of 26 cases (92%)
Disease activity and laboratory parameters
- No significant changes
Original publication
Overcoming methotrexate intolerance in a paediatric cohort of patients with rheumatic diseases: successful application of a large interval oral split-dose regimen. Clin Exp Rheumatol. Published 9 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →